Australian biotech AdvanCell nabs $112M Series C for radiopharmaceuticals
Summary
Ra\xaddio\xadphar\xadma\xadceu\xadti\xadcals biotech Ad\xadvan\xadCell has pulled to\xadgeth\xader a $112 mil\xadlion Se\xadries C about two years af\xadter its much small\xader Se\xadries B of Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected